3//SEC Filing
CK Life Sciences Intl (Holdings) Inc 3
Accession 0001104659-24-109541
CIK 0001818844other
Filed
Oct 16, 8:00 PM ET
Accepted
Oct 17, 4:29 PM ET
Size
9.6 KB
Accession
0001104659-24-109541
Insider Transaction Report
Form 3
CK Life Sciences Intl (Holdings) Inc
Director10% OwnerOther
Holdings
Series A Preferred Stock
→ Common Stock (21,083,854 underlying)- 211,383
Common Stock
Sealbond Ltd
Director10% OwnerOther
Holdings
Series A Preferred Stock
→ Common Stock (21,083,854 underlying)- 211,383
Common Stock
Footnotes (2)
- [F1]Sealbond Limited, a British Virgin Islands limited company ("Sealbond"), is a wholly-owned subsidiary of Kamfull Limited, a British Virgin Islands limited company ("Kamfull"). Kamfull is a wholly owned subsidiary of Biotech Strategic Holdings Ltd, a British Virgin Islands limited company ("Biotech Strategic). Biotech Strategic is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability ("CKLS"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.
- [F2]Following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share ("Series A Preferred Stock"), into shares of Common Stock, each share of the Series A Preferred Stock will be convertible into 10,000 shares of Common Stock, subject to waiver by the Reporting Person of a beneficial ownership limitation of 19.99% of the outstanding Common Stock. The shares of Series A Preferred Stock have no expiration date. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.
Documents
Issuer
Dogwood Therapeutics, Inc.
CIK 0001818844
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001297567
Filing Metadata
- Form type
- 3
- Filed
- Oct 16, 8:00 PM ET
- Accepted
- Oct 17, 4:29 PM ET
- Size
- 9.6 KB